Profile data is unavailable for this security.
About the company
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
- Revenue in USD (TTM)0.00
- Net income in USD-135.32m
- Incorporated2022
- Employees49.00
- LocationOculis Holding AGBahnhofstrasse 20ZUG 6300SwitzerlandCHE
- Phone+41 417113960
- Websitehttps://oculis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.55bn | 74.00 | -- | 9.26 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.56bn | 28.00 | -- | 3.22 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.56bn | 31.00 | -- | 19.42 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.59bn | 65.00 | -- | 3.33 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.60bn | 317.00 | -- | 2.95 | -- | 19.10 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Agios Pharmaceuticals Inc | 54.03m | -412.78m | 1.64bn | 539.00 | -- | 1.37 | -- | 30.32 | -7.12 | -7.12 | 0.932 | 20.41 | 0.0365 | 0.2096 | 7.36 | 100,237.50 | -27.89 | -10.70 | -29.52 | -11.34 | 88.26 | -- | -764.01 | -516.35 | 11.06 | -- | 0.00 | -- | 48.03 | -- | -161.27 | -- | -21.96 | -- |
| Oculis Holding AG | 0.00 | -135.32m | 1.65bn | 49.00 | -- | 9.37 | -- | -- | -2.82 | -2.82 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -70.95 | -- | -89.74 | -- | -- | -- | -- | -- | -- | -21.76 | 0.0185 | -- | -- | -- | 3.41 | -- | -- | -- |
| Ardelyx Inc | 398.23m | -56.55m | 1.67bn | 395.00 | -- | 10.82 | -- | 4.19 | -0.2364 | -0.2364 | 1.66 | 0.635 | 0.9326 | 2.57 | 6.14 | 1,008,187.00 | -13.24 | -35.80 | -16.15 | -45.22 | 88.21 | 86.06 | -14.20 | -80.49 | 4.11 | -2.07 | 0.5671 | -- | 168.06 | 129.14 | 40.76 | -- | 25.48 | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.40 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Sionna Therapeutics Inc | 0.00 | -70.68m | 1.67bn | 48.00 | -- | 5.19 | -- | -- | -1.61 | -1.61 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -26.35 | -- | -27.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.68bn | 580.00 | -- | -- | -- | 2.80 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.69bn | 263.00 | -- | 5.35 | -- | 12.58 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Pharvaris NV | 0.00 | -194.01m | 1.69bn | 108.00 | -- | 4.64 | -- | -- | -3.46 | -3.46 | 0.00 | 5.70 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.71bn | 43.00 | -- | 4.39 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.74bn | 155.00 | -- | 8.99 | -- | 26.11 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| MannKind Corp | 313.79m | 28.76m | 1.74bn | 407.00 | 61.12 | -- | 46.76 | 5.54 | 0.0926 | 0.0926 | 1.02 | -0.1451 | 0.6545 | 2.52 | 17.64 | 770,975.40 | 6.00 | -14.54 | 7.40 | -19.49 | 78.49 | 65.89 | 9.16 | -28.96 | 3.04 | 2.68 | 1.14 | -- | 43.50 | 35.27 | 331.09 | -- | 30.46 | -- |
Data as of Feb 17 2026. Currency figures normalised to Oculis Holding AG's reporting currency: US Dollar USD
10.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gildi - L�feyrissj��ur (Investment Management)as of 31 Dec 2025 | 2.45m | 4.28% |
| abrdn, Inc.as of 31 Dec 2025 | 1.75m | 3.06% |
| HBM Partners AG (Investment Management)as of 30 Jun 2025 | 500.00k | 0.88% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 331.33k | 0.58% |
| Syquant Capital SASas of 31 Dec 2025 | 192.72k | 0.34% |
| Folketrygdfondetas of 31 Dec 2025 | 182.80k | 0.32% |
| Propel Bio Management LLCas of 31 Dec 2025 | 172.84k | 0.30% |
| NEXTBio Capital Management LPas of 31 Dec 2025 | 149.75k | 0.26% |
| Banque Lombard Odier & Cie SA (Investment Management)as of 31 Dec 2025 | 107.30k | 0.19% |
| Acuta Capital Partners LLCas of 30 Sep 2025 | 101.78k | 0.18% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
